Together, these data support the hypothesis that the triple therapy might hamper the capacity of MYCN-amplified NB to efficiently utilize β-oxidation due to the inhibition of complex I, compromising the ability of mitochondria to sustain the elevated energy and anabolic demands of MYCN-amplified NB. This evidence concerns the gene MYCN and neuroblastoma.